A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
296 Downloads (Pure)

Abstract

BACKGROUND: The immunosuppressive agents mycophenolate acid (MPA) and tacrolimus (Tac) are associated with a higher incidence of BK polyomavirus nephropathy (BKPyVAN). In this observational retrospective cohort study, the frequency of BK polyomavirus (BKPyV) complications over a 24-month period was studied.

METHODS: 358 renal transplant recipients (RTR) treated with MPA, with either cyclosporine A (CsA) (CsAM group) or Tac (TacM group) and mostly prednisolone, were included.

RESULTS: Incidence of BKPyV-viremia was not significantly different between the CsAM (n = 42/191) (22.0%) and the TacM (n = 36/167) (21.6%) group. Biopsy proven BKPyVAN occurred more often in the TacM group (6.6%) versus the CsAM group (2.1%) (p = 0.03). Longitudinal data analysis showed a significant earlier decline of viral load in plasma in the CsAM group compared to the TacM group (p = 0.005). The incidence of biopsy proven acute rejection (BPAR) was significantly higher in the CsAM (19.9%) compared to the TacM (10.8%) (p = 0.02) group. Graft loss, estimated glomerular filtration rate and mortality rate did not differ in both treatment groups.

CONCLUSION: In conclusion, this study shows that immunosuppressive treatment with Tac and MPA compared to CsA and MPA is associated with a lower incidence of BPAR, but at the cost of an increased risk of developing BKPyVAN in the first two years post-transplant.

Original languageEnglish
Article numbere0178801
Number of pages17
JournalPLoS ONE
Volume12
Issue number6
DOIs
Publication statusPublished - 13-Jun-2017

Keywords

  • VIRUS-ASSOCIATED NEPHROPATHY
  • CYCLOSPORINE-A
  • RISK-FACTORS
  • IMMUNOSUPPRESSIVE AGENTS
  • CALCINEURIN INHIBITORS
  • ALLOGRAFT RECIPIENTS
  • MYCOPHENOLIC-ACID
  • CLINICAL-COURSE
  • CONTROL REGION
  • UNITED-STATES

Cite this